New cancer clinical trial: Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Published on: April 25, 2018 at 12:00PM
Condition:   Breast Cancer
Interventions:   Drug: Letrozole Plus Low-Dose Metronomic Capecitabine;   Drug: EC-T
Sponsor:   Guangdong General Hospital
Recruiting
https://ift.tt/2r0Ch6l